Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Dexamethasone in Relapsed/Refractory AL Amyloidosis
NCT03000660Phase 1Terminated
- Sponsor
- Tufts Medical Center
- Start
- Jan 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in amyloid light chain amyloidosis, sponsored by Tufts Medical Center. Primary endpoint: Participants with treatment related adverse events up to 8 months. Started Jan 2017; status: terminated.
02
Drugs
venetoclax
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03000660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000660.